Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CTI BioPharma
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with advanced ovarian carcinoma, who have failed one prior platinum and taxane containing regimen
Only one prior chemotherapy containing either cisplatin or carboplatin plus taxanes administered concomitantly
At least one measurable lesion according to RECIST
ECOG performance status 0 or 1
at least 18 years old
Adequate haematological function
Adequate renal and hepatic functions
Normal coagulation parameters
You may not be if
Platinum-sensitive patients (Group 2) who responded (CR or PR) to a 1st line therapy and subsequently progressed or relapsed after a treatment-free interval of \> 12 months
Pregnant or lactating patients
Prior treatment with camptothecins
Presence or history of CNS metastasis or carcinomatous leptomeningitis;
Current active infection per investigator assessment;
Unresolved bowel obstruction or subobstruction, uncontrolled Crohn's disease or ulcerative colitis;
Current history of chronic diarrhea \>= grade 1 (CTCAE version 3);
Surgery or radiotherapy ≤ 4 weeks before first study treatment. In case of cytoreductive surgery for the progression of the disease, ≤ 2 weeks before the 1st study treatment are allowed;
Other uncontrolled, serious illness or medical condition, as determined by the investigator;
Concomitant (or within 4 weeks before inclusion) administration of any other experimental drug under investigation;
Concurrent treatment with any other anti-cancer therapy;
Known HIV positivity or AIDS-related illness;
Patients who cannot be regularly followed up for psychological, social, familial or geographic reasons.